CD274 and neoplasm: The FDA recently confirmed (13 October 2021) that a combination of pembrolizumab and chemotherapy drugs, with or without bevacizumab, can have therapeutic benefits for patients with recurrent metastatic cervical cancer whose tumour cells express high levels of PD-L1 [39].